Abstract
Deciphering the relationships between genes and complex traits could help us better understand the biological mechanisms leading to phenotypic variations and disease onset. Univariate gene-based analyses are widely used to characterize gene-phenotype relationships, but are subject to the influence of confounders. Furthermore, while some genes directly contribute to traits variations, others may exert their effects through other genes. How to quantify individual genes’ direct and indirect effects on complex traits remains an important yet challenging question.
We presented a novel framework to decipher the total and direct causal effects of individual genes using imputed gene expression data from GWAS and raw gene expression from GTEx. The study was partially motivated by the quest to differentiate “core” genes (genes with direct causal effect on the phenotype) from “peripheral” ones. Our proposed framework is based on a Bayesian network (BN) approach, which produces a directed graph showing the relationship between genes and the phenotype. The approach aims to uncover the overall causal structure, to examine the role of individual genes and quantify the direct and indirect effects by each gene.
An important advantage and novelty of the proposed framework is that it allows gene expression and disease trait(s) to be evaluated in different samples, significantly improving the flexibility and applicability of the approach. It uses IDA and jointIDA incorporating a novel p-value-based regularization approach to quantify the causal effects (including total causal effects, direct causal effects, and medication effects) of genes. The proposed approach can be extended to decipher the joint causal network of 2 or more traits, and has high specificity and precision (a.k.a., positive predictive value), making it particularly useful for selecting genes for follow-up studies.
We verified the feasibility and validity of the proposed framework by extensive simulations and applications to 52 traits in the UK Biobank (UKBB). Split-half replication and stability selection analyses were performed to demonstrate the accuracy and efficiency of our proposed method to identify causally relevant genes. The identified (direct) causal genes were found to be significantly enriched for genes highlighted in the OpenTargets database, and the enrichment was stronger than achieved by conventional univariate gene-based tests. Encouragingly, many enriched pathways were supported by the literature, and some of the enriched drugs have been tested or used to treat patients in clinical practice. Our proposed framework provides powerful a way to prioritize genes with large direct or indirect causal effects and to quantify the importance of such genes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported partially by a National Natural Science Foundation China (NSFC) Young Scientist Grant (31900495), a National Natural Science Foundation China grant (81971706), the Lo Kwee Seong Biomedical Research Fund from The Chinese University of Hong Kong and the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank study has received ethical approval from the NHS National Research Ethics Service North West (16/NW/0274). The current study was conducted under the project number 28732.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The UK Biobank data is available to qualified researchers upon application.
